Almac and TTP Labtech form Alliance in Fluorescence Lifetime Technology
News Jan 08, 2013
FLT as a reading modality offers a robust, antibody-free, homogeneous assay platform which enables the user to avoid interference from fluorescent compounds within a screening library. Developed utilising experience in peptide engineering and chemical synthesis and design, Almac’s FLEXYTE™ assays harness the power and potential of FLT to provide an efficient and economical platform for screening and profiling. The evolving assay platform offers solutions for many major therapeutic target classes including kinases, proteases, phosphatases, DUB and an increasing number of epigenetic targets.
TTP Labtech’s Ameon™ system represents the next generation of FLT reader technology. By offering real-time decay curve analysis, the Ameon™ system provides a revolutionary combination of speed, precision, and data quality for FLT assays that can be readily integrated into HTS workflows.
‘The development of the Ameon™ reader by TTP Labtech has introduced an exciting new dimension to FLT technology and we are pleased that Almac’s FLEXYTE™ customers will be able to benefit from this advance in reader technology’ said Dr Stephen Barr, President and Managing Director of Almac Sciences.
‘We are excited by the potential of the FLEXYTE™ and Ameon™ reader combination to deliver robust, cost-effective screening results and enhanced productivity through better discrimination of lead compounds’ said Dr Wayne Bowen, Chief Scientific Officer of TTP Labtech.
Researchers Develop New Method to Generate Human AntibodiesNews
Researchers hope their approach will help researchers rapidly generate therapeutic antibodies for the treatment of infectious diseases and other conditions such as cancer.READ MORE
Large-Scale Production of Living Brain Cells Enables Entirely New ResearchNews
After performing a biopsy on the patient, the skin cells are transformed into brain cells that effectively imitate the disease and the age of the patient.READ MORE
U.S. Study of Dapivirine Ring in Lactating Women Finds Little Drug Gets Into Breast MilkNews
The antiretroviral drug dapivirine that is released from an experimental vaginal ring to protect against HIV is absorbed in very low concentrations into breastmilk.READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018